🔴 Cue Biopharma is trading 10% down with no confirmed company-specific explanation

Cue Biopharma is trading 10.08% lower at $22.13 on October 13, 2026, with no confirmed company-specific announcement explaining the decline.

• B. Riley’s Buy rating is positive but does not clearly explain the drop.
• Reports of positive CUE-221 trial results predate the move.
• Biotech shares are weaker, with XBI down 2.01%, while major market indexes are nearly flat. Sector weakness may contribute but does not fully account for Cue Biopharma’s sharper decline.